Conduritol B epoxide

Name: Conduritol B epoxide
Brand: MedChemExpress
SKU: HY-100944
Rating: 5.0 (12 reviews)

Cat. No.: HY-100944 Purity: 99.92%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Conduritol B epoxide is an irreversible covalently bound acid β-glucosidase (GCase) inhibitor.

For research use only. We do not sell to patients.

CAS No. : 6090-95-5

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 12 publication(s) in Google Scholar

Other Forms of Conduritol B epoxide:

Conduritol B epoxide (Standard) Get quote

12 Publications Citing Use of MCE Conduritol B epoxide

Cell Imaging/Staining

Bio/Physico-chemical Assay

: Conduritol B epoxide purchased from MedChemExpress. Usage Cited in: Neuromolecular Med. 2025 May 21;27(1):42. [Abstract]; GCase activity. SH-SY5Y cells were treated with Conduritol B epoxide (CBE) at concentrations of 10 and 100 μM to induce GCase dysfunction and cultured for 4days.

: Conduritol B epoxide purchased from MedChemExpress. Usage Cited in: Neuromolecular Med. 2025 May 21;27(1):42. [Abstract]; GCase protein level. SH-SY5Y cells were treated with Conduritol B epoxide (CBE) at concentrations of 10 and 100 μM to induce GCase dysfunction and cultured for 4days.

: Conduritol B epoxide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 16;15(1):1434. [Abstract]; a Representative images of mouse tau (T49) and MAP2 co-staining of WT neurons at DIV21 after ADtau seeding in the presence of vehicle or 200 μM Conduritol B epoxide (CBE). b Representative images of mouse tau (T49) and MAP2 co-staining of WT and Grn−/− neurons at DIV21 after seeding AD-tau.

: Conduritol B epoxide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Feb 16;15(1):1434. [Abstract]; Quantification of endogenous mouse tau-positive area within MAP2 area. Neurons were seeded with AD-tau in the absence or presence of vehicle, 2 μM, 20 μM or 200 μM Conduritol B epoxide (CBE) for 21 days.

: Conduritol B epoxide purchased from MedChemExpress. Usage Cited in: Neuron. 2020 Mar 4;105(5):822-836.e7. [Abstract]; Primary hippocampal neurons treated with Conduritol B epoxide (CBE;0-1000 μM) were lysed to determine GCase activity at 21 DIV. The plotted line is a non-linear fit of values with an estimated IC50 of 15.8 nM (n=3/group).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Conduritol B epoxide is an irreversible covalently bound acid β-glucosidase (GCase) inhibitor.

In Vitro

Treating N2a and Conduritol B epoxide-N2a cells with G6 gave GC reductions to 7% and 26% of untreated levels, respectively. G6 treated Conduritol B epoxide-N2a also has significantly decreased GS. Co-treatment of G6 and dantrolene of Conduritol B epoxide-N2a cells lead to a similar degree of GC and GS reduction as G6 alone, indicating a specific effect of G6 on inhibition of substrate accumulation, Conduritol B epoxide-N2a cells have higher calcium levels than in N2a cells without caffeine at baseline. Conduritol B epoxide-N2a cells show a significant increase in cytosolic calcium levels compared to N2a cells. Conduritol B epoxide-N2a cells show a significant reduction in OCR as evidenced by approximately 50% in all the parameters, including rate of ATP production, basal respiration, and maximal respiration, compared to N2a cells, indicating reduced mitochondrial function in this nGD cell model. In dantrolene-treated Conduritol B epoxide-N2a cells, levels of Ryr3 are increased to 76% of WT level^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Conduritol B epoxide treatment of 4L, 9H, 9V and WT mice (100 mg/kg/day, i.p.) from postnatal day 5 to 11 does not induce α-synuclein aggregates. Long-term daily Conduritol B epoxide treatment of 4L mice (100 mg/kg/day, from postnatal day 15 for 24 or 36 doses) leads to hind limb paralysis and small amounts of α-synuclein accumulation in the olfactory bulb, brainstem, and PVP near D3V (dorsal 3rd ventricle)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

162.14

Formula

C₆H₁₀O₅

CAS No.

6090-95-5

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H]2[C@@H]1O2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (616.75 mM; Need ultrasonic)

DMSO : 50 mg/mL (308.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.1675 mL	30.8375 mL	61.6751 mL
5 mM	1.2335 mL	6.1675 mL	12.3350 mL
10 mM	0.6168 mL	3.0838 mL	6.1675 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (15.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (616.75 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (283 KB) SDS (392 KB)

COA (256 KB) HNMR (252 KB) RP-HPLC (241 KB) MS (72 KB)

Handling Instructions (2659 KB)

References

[1]. Liou B, et al. Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Hum Mol Genet. 2016 Sep 20. pii: ddw322. [Epub ahead of print] [Content Brief]

[2]. YH Xu, et al. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. Author manuscript; available in PMC 2012 Apr 1

Kinase Assay ^[1]	Cells are homogenized in 1% sodium taurocholate/1% Triton X-100. GCase activity is determined fluorometrically using 4MU-Glucose as the substrate in 0.25% sodium taurocholate, 0.25% Triton X-100 and 0.1M citric-phosphate buffer (pH 5.6). Brain tissues are homogenized in 1X PBS and incubated in 5 µM brain phosphatidylserine and 0.1M citric-phosphate buffer (pH 5.6) for GCase activity assay using 4MU-Glucose as substrate. Protein concentrations are determined by BCA assay using BSA as standard. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Gba1 point mutated 4L, 9H and 9V mice or WT mice are intraperitoneally injected with 100 mg/kg/day of Conduritol B epoxide. In short-term experiments, daily injections are initiated at postnatal day 5 and continued for 6 daily doses. The mice are sacrificed on day 12 or 2 months after last injection. In long-term experiments, 4L mice are injected daily beginning at postnatal day 15 for 24 or 36 daily doses and sacrificed the day after last injection. Mice are perfused with PBS and organs are harvested for enzyme activity, lipid and histological analyses. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Liou B, et al. Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Hum Mol Genet. 2016 Sep 20. pii: ddw322. [Epub ahead of print] [Content Brief] [2]. YH Xu, et al. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. Author manuscript; available in PMC 2012 Apr 1

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	6.1675 mL	30.8375 mL	61.6751 mL	154.1877 mL
	5 mM	1.2335 mL	6.1675 mL	12.3350 mL	30.8375 mL
	10 mM	0.6168 mL	3.0838 mL	6.1675 mL	15.4188 mL
	15 mM	0.4112 mL	2.0558 mL	4.1117 mL	10.2792 mL
	20 mM	0.3084 mL	1.5419 mL	3.0838 mL	7.7094 mL
	25 mM	0.2467 mL	1.2335 mL	2.4670 mL	6.1675 mL
	30 mM	0.2056 mL	1.0279 mL	2.0558 mL	5.1396 mL
	40 mM	0.1542 mL	0.7709 mL	1.5419 mL	3.8547 mL
	50 mM	0.1234 mL	0.6168 mL	1.2335 mL	3.0838 mL
	60 mM	0.1028 mL	0.5140 mL	1.0279 mL	2.5698 mL
	80 mM	0.0771 mL	0.3855 mL	0.7709 mL	1.9273 mL
	100 mM	0.0617 mL	0.3084 mL	0.6168 mL	1.5419 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.